Janux Therapeutics Inc. (JANX), a clinical-stage biopharmaceutical company, Thursday, priced an underwritten public offering of 5.32 million shares at $63.00 per share.
The pre-funded warrants to purchase 238,095 shares of common stock are priced at $62.999 per pre-funded warrant.
The underwriters have a 30-day option to purchase up to an additional 833,333 shares of the company's common stock.
The transaction, which is expected to rake in gross proceeds of $350.0 million, is slated to close on or by December 6, 2024, subject to certain conditions.
JANX closed yesterday's trading at $66.83, up 11.65%. In premarket trading today, the stock is up another 0.40% at $67.10.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.